TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 38653350

Group type: EXPERIMENTAL
Intervention: Ketamine
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Ketamine/esketamine post-discharge
Number of subjects: 203

Group type: COMPARATOR
Intervention: Control group (non-ketamine studies)
Number of subjects: 203
Study: 38653496

Group type: EXPERIMENTAL
Intervention: Colectomy with the novel miniaturized robotic-assisted surgery device
Number of subjects: 30
Study: 38653508

Group type: EXPERIMENTAL
Intervention: Epirubicin (3.75, 7.5 or 15 mg/m2)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Epirubicin
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 38653513

Group type: EXPERIMENTAL
Intervention: Mindmore Remote digitalized neuropsychological test battery
Number of subjects: 300

Group type: COMPARATOR
Intervention: Traditional neuropsychological assessment face-to-face
Number of subjects: 300
Study: 38653618

Group type: EXPERIMENTAL
Intervention: Empagliflozin 25mg once daily for three months
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo tablets once daily for three months
Number of subjects: 50
Study: 38653808

Group type: EXPERIMENTAL
Intervention: Acacia fiber (AF) 10 g
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Probiotic Bifidobacterium Lactis (BLa80) 4 g
Number of subjects: 180

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study: 38653864

Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 35
Study: 38653903

Group type: EXPERIMENTAL
Intervention: iGlarLixi (Suliqua) administered once daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: MDI regimen continuation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: iGlarLixi
Number of subjects: 0
Study: 38653979

Group type: EXPERIMENTAL
Intervention: rAAV2/8-hCYP4V2 gene therapy (single unilateral subretinal injection of 7.5 × 10^11 vg)
Number of subjects: 12
Study: 38653983

Group type: EXPERIMENTAL
Intervention: Umbilical cord-derived mesenchymal stem cells (UC-MSCs) administered at escalating doses of 0.5 × 10^6 cells/kg.
Number of subjects: 18
Study: 38654004

Group type: EXPERIMENTAL
Intervention: Cervicocranial flexion exercise (CCFE) and neck flexor endurance training plus normal cardiopulmonary rehabilitation
Number of subjects: 13

Group type: COMPARATOR
Intervention: General neck stretching exercises plus cardiopulmonary rehabilitation
Number of subjects: 13
Study: 38654151

Group type: EXPERIMENTAL
Intervention: Cardiac arrhythmias (≥2 kinds of arrhythmias)
Number of subjects: 23825

Group type: EXPERIMENTAL
Intervention: Ventricular tachyarrhythmias
Number of subjects: 23825

Group type: EXPERIMENTAL
Intervention: Bradyarrhythmias
Number of subjects: 23825

Group type: EXPERIMENTAL
Intervention: Atrial tachyarrhythmias
Number of subjects: 23825

Group type: EXPERIMENTAL
Intervention: Any arrhythmias
Number of subjects: 23825
Study: 38654198

Group type: EXPERIMENTAL
Intervention: Exercise rehabilitation triage and referral system
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Qualitative analysis of semi-structured interviews
Number of subjects: 100
Study: 38654329

Group type: EXPERIMENTAL
Intervention: Problem-solving therapy (PST) provided by general practitioners or general practice staff after a 2-day PST course
Number of subjects: 188

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Problem-solving therapy (PST)
Number of subjects: 188
Study: 38654367

Group type: EXPERIMENTAL
Intervention: Power Wheelchair driving simulator (VR)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Real circuit driving (R)
Number of subjects: 31
Study: 38654416

Group type: EXPERIMENTAL
Intervention: Highly effective disease-modifying therapy
Number of subjects: 8557

Group type: COMPARATOR
Intervention: Moderately effective disease-modifying therapy
Number of subjects: 8557

Group type: EXPERIMENTAL
Intervention: Overall disease-modifying therapy exposure
Number of subjects: 8557

Group type: EXPERIMENTAL
Intervention: Age-adjusted prevalence of MS
Number of subjects: 8557

Group type: EXPERIMENTAL
Intervention: Prevalence by demographic subgroup
Number of subjects: 8557
Study: 38654422

Group type: EXPERIMENTAL
Intervention: Vonoprazan 10 mg once daily for 24 weeks
Number of subjects: 703

Group type: EXPERIMENTAL
Intervention: Vonoprazan 20 mg once daily for 24 weeks
Number of subjects: 703

Group type: COMPARATOR
Intervention: Lansoprazole 15 mg once daily for 24 weeks
Number of subjects: 703

Group type: EXPERIMENTAL
Intervention: Vonoprazan 10 mg at 12 weeks
Number of subjects: 703

Group type: EXPERIMENTAL
Intervention: Vonoprazan 20 mg at 12 weeks
Number of subjects: 703

Group type: COMPARATOR
Intervention: Lansoprazole at 12 weeks
Number of subjects: 703

Group type: EXPERIMENTAL
Intervention: Vonoprazan 10 mg
Number of subjects: 703

Group type: EXPERIMENTAL
Intervention: Vonoprazan 20 mg
Number of subjects: 703

Group type: COMPARATOR
Intervention: Lansoprazole
Number of subjects: 703
Study: 38654565

Group type: EXPERIMENTAL
Intervention: P2Y12 inhibitor monotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Prolonged DAPT (12-month or longer)
Number of subjects: 0
Study: 38654917

Group type: EXPERIMENTAL
Intervention: Supervised and home-based exercise training
Number of subjects: 50
Study: 38655380

Group type: EXPERIMENTAL
Intervention: Digital mental health interventions (DMHIs) for adolescent depression prevention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Screening and recruitment activities for the P2P trial
Number of subjects: 0
Study: 38655672

Group type: EXPERIMENTAL
Intervention: Surefil One self-adhesive bulk-fill composite
Number of subjects: 64

Group type: COMPARATOR
Intervention: Filtek One bulk-fill composite with Scotchbond Universal adhesive in self-etch mode
Number of subjects: 64
Study: 38655676

Group type: EXPERIMENTAL
Intervention: NTHi vaccine antigens
Number of subjects: 0
Study: 38655693

Group type: EXPERIMENTAL
Intervention: Pulmonary vein isolation using a variable-loop circular catheter with 3D mapping integration
Number of subjects: 186
Study: 38655793

Group type: EXPERIMENTAL
Intervention: Structured weight management programs
Number of subjects: 0

Group type: COMPARATOR
Intervention: Obesity pharmacotherapeutics
Number of subjects: 0
Study: 38655842

Group type: EXPERIMENTAL
Intervention: TAF/EVG inserts (20 mg/16 mg) administered rectally
Number of subjects: 0
Study: 38655852

Group type: EXPERIMENTAL
Intervention: Gentle Yoga and Yogic Breathing
Number of subjects: 20
Study: 38655990

Group type: EXPERIMENTAL
Intervention: Probiotic drink containing Actiregularis strain (5×106 cfu/ml) added to maternal diet once daily for 15 days
Number of subjects: 0
Study: 38655998

Group type: EXPERIMENTAL
Intervention: Rocuronium priming (10% of the rocuronium dose administered 3 min before induction)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Standard rapid sequence intubation
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Rocuronium priming
Number of subjects: 52
Study: 38656145

Group type: EXPERIMENTAL
Intervention: Robotic-assisted patellofemoral arthroplasty (PFA)
Number of subjects: 44
Study: 38656217

Group type: EXPERIMENTAL
Intervention: Doxycycline postexposure prophylaxis (doxy-PEP)
Number of subjects: 44
Study: 38656229

Group type: EXPERIMENTAL
Intervention: Androgen deprivation therapy (ADT) with luteinizing hormone-releasing hormone antagonist degarelix
Number of subjects: 29
Study: 38656252

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 38656355

Group type: EXPERIMENTAL
Intervention: Aronia melanocarpa extract (AME) 180 mg anthocyanins/day
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 38656372

Group type: EXPERIMENTAL
Intervention: Obesity Surgery (OS)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Low-Calorie Diet (LCD)
Number of subjects: 24
Study: 38656413

Group type: EXPERIMENTAL
Intervention: Dual-ring, plastic wound protector
Number of subjects: 457

Group type: COMPARATOR
Intervention: Surgical gauze (control)
Number of subjects: 457
Study: 38656557

Group type: EXPERIMENTAL
Intervention: Alpibectir (0.5 to 40 mg) administered as single daily doses in fasted and fed conditions.
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Alpibectir (5 to 30 mg) administered once daily for 7 days in multiple ascending doses.
Number of subjects: 80

Group type: COMPARATOR
Intervention: Alpibectir under fed conditions (10 mg).
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Alpibectir (various doses) in multiple ascending doses.
Number of subjects: 80
Study: 38656566

Group type: EXPERIMENTAL
Intervention: Caspofungin
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Fluconazole
Number of subjects: 190

Group type: COMPARATOR
Intervention: CDSS
Number of subjects: 190
Study: 38656579

Group type: EXPERIMENTAL
Intervention: MP (migraine as patient)
Number of subjects: 366

Group type: EXPERIMENTAL
Intervention: MH (migraine as healthy)
Number of subjects: 366

Group type: COMPARATOR
Intervention: HC (headache-free controls)
Number of subjects: 366
Study: 38656736

Group type: EXPERIMENTAL
Intervention: BI 1358894 (100 mg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: BI 1358894 (200 mg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: BI 1358894 (50 mg and 100 mg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: BI 1358894
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 38656781

Group type: EXPERIMENTAL
Intervention: Patient-reported outcomes (PRO) intervention
Number of subjects: 152
Study: 38656931

Group type: EXPERIMENTAL
Intervention: Cetuximab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Supportive care
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All participants
Number of subjects: 0
Study: 38656951

Group type: EXPERIMENTAL
Intervention: Cafeteria intervention encouraging healthy foods and discouraging unhealthy foods for six months
Number of subjects: 277
Study: 38657001

Group type: EXPERIMENTAL
Intervention: Remdesivir
Number of subjects: 642

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 642
Study: 38657084

Group type: EXPERIMENTAL
Intervention: MVA-BN-Filo, Ad26.ZEBOV administered 14 days apart (n = 79)
Number of subjects: 499

Group type: EXPERIMENTAL
Intervention: Ad26.ZEBOV, MVA-BN-Filo administered 28 days apart (n = 322)
Number of subjects: 499

Group type: COMPARATOR
Intervention: Saline/placebo (n = 98)
Number of subjects: 499

Group type: EXPERIMENTAL
Intervention: Both vaccine regimens (14-day and 28-day)
Number of subjects: 499
Study: 38657201

Group type: EXPERIMENTAL
Intervention: Teclistamab (1.5 mg/kg)
Number of subjects: 165
Study: 38657227

Group type: EXPERIMENTAL
Intervention: MASP+ app
Number of subjects: 72

Group type: COMPARATOR
Intervention: National Cancer Institute's QuitGuide app
Number of subjects: 72
Study: 38657244

Group type: EXPERIMENTAL
Intervention: Sequential CD7 CAR T-cell therapy
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Haploidentical HSCT without pharmacologic myeloablation or GVHD prophylaxis
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Disease-free survival
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Follow-up after CAR T-cell therapy
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Remission status
Number of subjects: 10
Study: 38657265

Group type: EXPERIMENTAL
Intervention: Exagamglogene autotemcel (exa-cel)
Number of subjects: 52
Study: 38657345

Group type: EXPERIMENTAL
Intervention: Larotrectinib
Number of subjects: 93

Group type: COMPARATOR
Intervention: Control (Chemotherapy)
Number of subjects: 93
Study: 38657366

Group type: EXPERIMENTAL
Intervention: Niraparib
Number of subjects: 0
Study: 38657398

Group type: EXPERIMENTAL
Intervention: Music intervention
Number of subjects: 82

Group type: COMPARATOR
Intervention: Control group (no music)
Number of subjects: 82
Study: 38657530

Group type: EXPERIMENTAL
Intervention: ChatGPT-4 predictions
Number of subjects: 2851
Study: 38657730

Group type: EXPERIMENTAL
Intervention: Medical Management (MM)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MM plus Connections (CHESS health) digital smartphone application (MMD)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sublingual Buprenorphine with taper
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Extended-release Buprenorphine with taper
Number of subjects: 0
Study: 38657731

Group type: EXPERIMENTAL
Intervention: Telemedicine care for MS
Number of subjects: 120

Group type: COMPARATOR
Intervention: In-clinic care for MS
Number of subjects: 120
Study: 38657732

Group type: EXPERIMENTAL
Intervention: Digital, coach-assisted intervention targeting hope
Number of subjects: 150

Group type: COMPARATOR
Intervention: Attention control
Number of subjects: 150
Study: 38657773

Group type: EXPERIMENTAL
Intervention: Cariprazine (3-12 mg/d)
Number of subjects: 930

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 930
Study: 38657999

Group type: EXPERIMENTAL
Intervention: Photobiomodulation (PBM) treatment with moisturising cream, performed at 630 nm two times per week in palmoplantar areas (4 J/cm²)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sham PBM treatment with moisturising cream
Number of subjects: 40
Study: 38658010

Group type: EXPERIMENTAL
Intervention: Vaginal Hysterectomy (VH)
Number of subjects: 1000

Group type: COMPARATOR
Intervention: vNOTES (vaginal natural orifice transluminal endoscopic surgery)
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Laparoscopic Hysterectomy (LH)
Number of subjects: 1000
Study: 38658012

Group type: EXPERIMENTAL
Intervention: Fast-track total hip arthroplasty (THA)
Number of subjects: 1400

Group type: EXPERIMENTAL
Intervention: Fast-track total knee arthroplasty (TKA)
Number of subjects: 1400

Group type: EXPERIMENTAL
Intervention: Fast-track unicompartmental knee arthroplasty (UKA)
Number of subjects: 1400

Group type: EXPERIMENTAL
Intervention: Perioperative diabetes treatment
Number of subjects: 1400
Study: 38658017

Group type: EXPERIMENTAL
Intervention: Histological and molecular features assessment
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Molecular classification
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: p53 abnormality
Number of subjects: 223
Study: 38658024

Group type: EXPERIMENTAL
Intervention: Pamiparib, Tislelizumab, Bevacizumab, and Nab-Paclitaxel (biomarker-driven combinatorial therapies)
Number of subjects: 160
Study: 38658101

Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 19220

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19220
Study: 38658126

Group type: EXPERIMENTAL
Intervention: Transfemoral TAVR
Number of subjects: 1584

Group type: COMPARATOR
Intervention: SAVR
Number of subjects: 1584
Study: 38658128

Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve replacement (TAVR)
Number of subjects: 1863
Study: 38658392

Group type: EXPERIMENTAL
Intervention: Novel PSMA-targeting radionuclide therapy agents
Number of subjects: 0
Study: 38658398

Group type: EXPERIMENTAL
Intervention: Antioxidant-rich kindergarten meals (2-week meal plan including breakfast, lunch, and two snacks)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Standard kindergarten meal plans (control group)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Antioxidant-rich kindergarten meals
Number of subjects: 57
Study: 38658485

Group type: EXPERIMENTAL
Intervention: Vedolizumab
Number of subjects: 440

Group type: COMPARATOR
Intervention: Anti-TNFα agents
Number of subjects: 440

Group type: EXPERIMENTAL
Intervention: Vedolizumab (top 40% effect score distribution)
Number of subjects: 440

Group type: COMPARATOR
Intervention: Anti-TNFα agents (top 40% effect score distribution)
Number of subjects: 440
Study: 38658775

Group type: EXPERIMENTAL
Intervention: Autologous HER2-specific CAR T cells after lymphodepletion with fludarabine (Flu) ± cyclophosphamide (Cy)
Number of subjects: 0
Study: 38658877

Group type: EXPERIMENTAL
Intervention: Psilocybin (2 mg and 5 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 38659046

Group type: EXPERIMENTAL
Intervention: LCAR-B38M CAR T-cell therapy
Number of subjects: 74

Group type: COMPARATOR
Intervention: Subsequent therapies after PD
Number of subjects: 74
Study: 38659187

Group type: EXPERIMENTAL
Intervention: High-flow nasal cannula (HFNC) oxygenation at flow rates of 50-60 L/min
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 38659226

Group type: EXPERIMENTAL
Intervention: Oncolytic adenovirus H101
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control value
Number of subjects: 25
Study: 38659334

Group type: EXPERIMENTAL
Intervention: Rimegepant 75 mg up to once per day as EOD + PRN for 12 weeks
Number of subjects: 1800

Group type: EXPERIMENTAL
Intervention: Rimegepant PRN for up to 52 weeks
Number of subjects: 1800

Group type: EXPERIMENTAL
Intervention: Rimegepant (overall)
Number of subjects: 1800
Study: 38659874

Group type: EXPERIMENTAL
Intervention: CHW-led SBIRT intervention plus Alive!
Number of subjects: 440

Group type: COMPARATOR
Intervention: Usual care arm (CRC prevention educational pamphlets and a list of CRC screening sites)
Number of subjects: 440
Study: 38660060

Group type: EXPERIMENTAL
Intervention: Low-glucose eating (LGE)
Number of subjects: 17
Study: 38660112

Group type: EXPERIMENTAL
Intervention: Men undergoing TAVR
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Women undergoing TAVR
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Asian cohort (Men)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Asian cohort (Women)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Non-Asian cohort (Men)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Non-Asian cohort (Women)
Number of subjects: 0
Study: 38660276

Group type: EXPERIMENTAL
Intervention: Ramucirumab combined with nab-paclitaxel, lobaplatin, and S-1
Number of subjects: 140
Study: 38660371

Group type: EXPERIMENTAL
Intervention: Group phone calls (GP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Individual phone calls (IP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Enhanced usual care (EUC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Individual phone calls (IP) vs Enhanced usual care (EUC)
Number of subjects: 0
Study: 38660518

Group type: EXPERIMENTAL
Intervention: Active human MMP9 (act-hMMP9)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 38660794

Group type: EXPERIMENTAL
Intervention: OCT-guided PCI
Number of subjects: 419

Group type: COMPARATOR
Intervention: FFR-guided PCI
Number of subjects: 419

Group type: EXPERIMENTAL
Intervention: μQFR
Number of subjects: 419
Study: 38661071

Group type: EXPERIMENTAL
Intervention: Selpercatinib
Number of subjects: 6
Study: 38661180

Group type: COMPARATOR
Intervention: Proactive screening algorithm for early-onset pneumonia (EOP) implemented in study period 2.
Number of subjects: 190
Study: 38661449

Group type: EXPERIMENTAL
Intervention: Exagamglogene autotemcel (exa-cel)
Number of subjects: 44
Study: 38661512

Group type: EXPERIMENTAL
Intervention: Neoadjuvant therapy
Number of subjects: 0
Study: 38661602

Group type: EXPERIMENTAL
Intervention: AGN-151607 125 U
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: AGN-151607 250 U
Number of subjects: 312

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 312
Study: 38661649

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral intervention (TRACK)
Number of subjects: 0
Study: 38661677

Group type: EXPERIMENTAL
Intervention: Moderate-to-vigorous physical activity (MVPA)
Number of subjects: 17
Study: 38662147

Group type: EXPERIMENTAL
Intervention: Emapalumab 1 mg/kg (increasing to 3, 6, and up to 10 mg/kg based on clinical response) every 3 days for primary HLH
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Emapalumab 6 mg/kg followed by 3 mg/kg every 3 days until day 15 and twice weekly until day 28 for MAS in sJIA
Number of subjects: 58
Study: 38662232

Group type: EXPERIMENTAL
Intervention: Synbiotics (probiotics and inulin prebiotics)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Synbiotics
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Synbiotics and Probiotics
Number of subjects: 90

Group type: COMPARATOR
Intervention: Probiotics
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 38662300

Group type: EXPERIMENTAL
Intervention: Subthalamic deep brain stimulation (STN-DBS)
Number of subjects: 35
Study: 38662318

Group type: EXPERIMENTAL
Intervention: Recombinant zoster vaccine (RZV)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (unvaccinated)
Number of subjects: 0
Study: 38662320

Group type: EXPERIMENTAL
Intervention: Ganglionic local opioid analgesia (GLOA) at the superior cervical ganglion with a total volume of 2 ml injected into the parapharyngeal space and its 'medial compartment'.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ganglionic local opioid analgesia (GLOA) at the superior cervical ganglion.
Number of subjects: 0
Study: 38662364

Group type: EXPERIMENTAL
Intervention: Postoperative pelvic radiation using hypofractionated IMRT with 40 Gy in 16 fractions combined with concurrent chemotherapy
Number of subjects: 79
Study: 38662373

Group type: EXPERIMENTAL
Intervention: 3 overprescribing warning letters
Number of subjects: 346169

Group type: COMPARATOR
Intervention: Placebo letter
Number of subjects: 346169
Study: 38662372

Group type: EXPERIMENTAL
Intervention: Abatacept (10 mg/kg IV, max 1000 mg)
Number of subjects: 509

Group type: EXPERIMENTAL
Intervention: Modified higher-dose regimen of abatacept
Number of subjects: 509
Study: 38662520

Group type: EXPERIMENTAL
Intervention: Organized ACP conversation and summarizing palliative plan
Number of subjects: 144

Group type: COMPARATOR
Intervention: No organized ACP conversation and summarizing palliative plan
Number of subjects: 144
Study: 38662639

Group type: EXPERIMENTAL
Intervention: SHEN26
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study: 38662661

Group type: EXPERIMENTAL
Intervention: Joint Observation intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment-as-usual (Control)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both groups (Intervention and Control)
Number of subjects: 0
Study: 38662712

Group type: EXPERIMENTAL
Intervention: Dietary screening tool (27-item FFQ)
Number of subjects: 58
Study: 38662736

Group type: EXPERIMENTAL
Intervention: Basis pursuit denoising with polynomial detrending (BPWP) model
Number of subjects: 3
Study: 38662779

Group type: EXPERIMENTAL
Intervention: Direct oral anticoagulants (DOAC) adherence measured over 95 days
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Direct oral anticoagulants (DOAC) adherence for hemorrhagic events
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Direct oral anticoagulants (DOAC) adherence for ischemic events
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Timing adherence
Number of subjects: 33